Business Wire

STEVANATO-GROUP

Share

Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005581/en/

The agreement makes Stevanato Group an exclusive manufacturing partner for the device, offering a full set of capabilities to its pharmaceutical customers. Stevanato Group will mould the components for Aidaptus® and provide final and sub-assembly equipment, while also offering market-leading pre-filled syringes to enable pharmaceutical customers to create the final product for patient use. Assembly of the components will be undertaken by both Stevanato Group at its global manufacturing sites and by Owen Mumford at its automated assembly center of excellence in the UK.

The collaboration is intended to bring added value to customers, matching world-class device expertise with premium manufacturing capabilities. It is expected to streamline device production with the aim to and deliver the full value of the innovative Aidaptus® platform to the market.

Aidaptus® is a 2-step, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features plunger sensing technology with a self-adjusting plunger rod that automatically adapts to the individual plunger positions and different fill volumes in each syringe, with no change parts required. The auto-injector is also able to accommodate a unique variety of drug viscosities.

With over 70 years of experience, Stevanato Group supports pharmaceutical companies with the right degree of flexibility to meet their quality and productivity goals. With an integrated offer of precision injection moulding capabilities and modular assembly platforms, the company offers the possibility to scale production and move from clinical trial to high-volume production with extreme flexibility.

“Aidaptus® will help patients to self-administer their individual therapies using a simple and easy to use device,” said Adam Mumford, Director of Owen Mumford. “At the same time, this auto-injector can help reduce complexity, minimize supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies, thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes. Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”

Mauro Stocchi, Chief Business Officer of Stevanato Group, commented: "We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors. With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems."

“Stevanato Group is an established company with an excellent reputation in the pharmaceutical industry,” said Michael Earl, Director of Pharmaceutical Services at Owen Mumford. “It has deep expertise in complex moulding and assembly operations and will be a reliable source of quality components for our Aidaptus® auto-injector. Forming a collaboration with Stevanato Group will provide additional reach to enable more customers to benefit from the advantages of this innovative new platform.”

Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group, added: "The Aidaptus® auto-injector platform combines ease of use for patients with faster time-to-market access for pharma organizations. We aim to be the strategic partner with which to develop innovative combination products as we continue the expansion of our integrated capabilities in the drug delivery space, and for this reason we are very excited to work with Owen Mumford and provide access to its exciting new auto-injector platform."

The collaboration will be jointly launched at Pharmapack 2022. Stevanato Group will be pleased to present Aidaptus® and its portfolio of integrated solutions on May 18 and 19 at Pharmapack Europe, Paris Expo, booths no. B56 and B58.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. To learn more, visit stevanatogroup.com.

Forward-Looking Statements

This press release may include forward-looking statements. The words "aim", "opportunities" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs, or current expectations concerning, among other things, the Company's product offering, the potential use of the Company's products to treat different diseases, growth opportunities, market position, and the expansion of the Company's integrated capabilities. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators, and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com